Share Name Share Symbol Market Type
Johnson and Johnson NYSE:JNJ NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -0.52 -0.31% 166.58 168.72 166.3165 167.20 5,895,338 21:03:04

J&J's Janssen Gets Europe OK for Twice-Yearly Schizophrenia Treatment

23/11/2021 12:18pm

Dow Jones News

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart

From Nov 2021 to Jan 2022

Click Here for more Johnson and Johnson Charts.

By Colin Kellaher


Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Tuesday said the European Commission approved the company's Byannli six-month maintenance treatment for schizophrenia in adults.

The drugmaker said the approval, which covers patients who are clinically stable on monthly or three-month doses, makes Byannli the first twice-yearly treatment of schizophrenia in adults in Europe.

The U.S. Food and Drug Administration in September approved a six-month version of the antipsychotic, marketed in the U.S. as Invega.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

November 23, 2021 07:03 ET (12:03 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Johnson and Johnson Chart

1 Year Johnson and Johnson Chart

1 Month Johnson and Johnson Chart

1 Month Johnson and Johnson Chart
ADVFN Advertorial
Your Recent History
Johnson an..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220119 21:18:39